| 5122- | Sal, | Identification of selective inhibitors of cancer stem cells by high-throughput screening |
| - | in-vivo, | BC, | SUM159 | - | NA, | NA, | 4T1 |
| 5121- | Sal, | Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells |
| - | in-vitro, | BC, | NA |
| 3939- | SAMe, | VitB12, | ALC, | Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot Study |
| - | Trial, | NA, | NA |
| 3938- | SAMe, | S-adenosyl-L-methionine in the treatment of Alzheimer's disease |
| - | Human, | AD, | NA |
| 4115- | SAMe, | Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. |
| - | Review, | AD, | NA |
| 4114- | SAMe, | S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research |
| - | Review, | AD, | NA |
| 1210- | SANG, | Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer |
| - | in-vitro, | BC, | NA |
| 1209- | SANG, | Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration |
| - | in-vitro, | Lung, | A549 |
| 1208- | SANG, | Sanguinarine induces apoptosis in osteosarcoma by attenuating the binding of STAT3 to the single-stranded DNA-binding protein 1 (SSBP1) promoter region |
| - | in-vitro, | OS, | NA |
| 1307- | SANG, | Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway |
| - | in-vitro, | CRC, | HT-29 |
| 1090- | SANG, | Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression. |
| - | in-vitro, | BC, | MCF7 |
| 1134- | SANG, | Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 6446- | SAO, | Alpha-Santalol, a Component of Sandalwood Oil Inhibits Migration of Breast Cancer Cells by Targeting the β-catenin Pathway |
| - | in-vitro, | BC, | NA |
| 6440- | SAO, | Biological Properties of Sandalwood Oil and Microbial Synthesis of Its Major Sesquiterpenoids |
| - | Review, | Var, | NA |
| 6441- | SAO, | Sandalwood Album Oil as a Botanical Therapeutic in Dermatology |
| - | Review, | PSA, | NA |
| 6442- | SAO, | Medicinal properties of alpha-santalol, a naturally occurring constituent of sandalwood oil: review |
| - | Review, | RCC, | NA |
| 6443- | SAO, | α-Santalol, a derivative of sandalwood oil, induces apoptosis in human prostate cancer cells by causing caspase-3 activation |
| - | in-vitro, | Pca, | PC3 |
| 6444- | SAO, | Sandalwood oil by-product prevents prostate cancer development in mice |
| - | in-vivo, | Pca, | PC12 |
| 6445- | SAO, | Antineoplastic Effects of α-Santalol on Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancer Cells through Cell Cycle Arrest at G2/M Phase and Induction of Apoptosis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MCF-10AT |
| 6447- | SAO, | Autophagy Induction by α-Santalol in Human Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 6448- | SAO, | A novel chemopreventive mechanism for a traditional medicine: East Indian sandalwood oil induces autophagy and cell death in proliferating keratinocytes |
| - | in-vitro, | Nor, | HaCaT |
| 6449- | SAO, | Skin cancer chemoprevention by α-santalol |
| - | Review, | Melanoma, | A431 |
| 6450- | SAO, | Survivin Down-regulation by α-Santalol Is Not Mediated Through PI3K-AKT Pathway in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 6451- | SAO, | α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 3853- | SAS, | Sulfur-containing therapeutics in the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 5139- | SAS, | Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | U2OS |
| 5045- | SAS, | Sulfasalazine, a potent cystine-glutamate transporter inhibitor, enhances osteogenic differentiation of canine adipose-derived stem cells |
| - | in-vivo, | Var, | NA |
| 5044- | SAS, | xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma |
| - | in-vitro, | Var, | NA |
| 5043- | SAS, | Chronic Sulfasalazine Treatment in Mice Induces System xc− - Independent Adverse Effects |
| - | in-vivo, | Nor, | NA |
| 5042- | SAS, | xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling |
| - | Review, | Var, | NA |
| 5041- | SAS, | Cisplatin, | Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism |
| - | in-vitro, | CRC, | NA |
| 5040- | SAS, | Structure-Activity-Relationship-Aided Design and Synthesis of xCT Antiporter Inhibitors |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | BC, | MCF7 |
| 5141- | SAS, | Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B |
| - | in-vitro, | CRC, | SW-620 |
| 5140- | SAS, | Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β |
| - | in-vitro, | AML, | Jurkat | - | in-vitro, | CRC, | SW-620 |
| 5138- | SAS, | Rad, | Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion |
| - | vitro+vivo, | GBM, | NA |
| 5039- | SAS, | Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer |
| - | vitro+vivo, | BC, | NA |
| 5038- | SAS, | Rad, | Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma |
| - | in-vivo, | Melanoma, | B16-F10 |
| 5037- | SAS, | Inhibition of xCT by sulfasalazine alleviates the depression-like behavior of adult male mice subjected to maternal separation stress |
| - | in-vivo, | Nor, | NA |
| 5036- | SAS, | Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 5035- | SAS, | Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use |
| - | Human, | GC, | NA | - | in-vitro, | GC, | NCI-N87 | - | in-vitro, | GC, | SGC-7901 |
| 1388- | Sco, | Scoulerine promotes cell viability reduction and apoptosis by activating ROS-dependent endoplasmic reticulum stress in colorectal cancer cells |
| - | in-vitro, | CRC, | NA |
| 1403- | SDT, | BBR, | From 2D to 3D In Vitro World: Sonodynamically-Induced Prooxidant Proapoptotic Effects of C60-Berberine Nanocomplex on Cancer Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | LLC1 |
| 2549- | SDT, | Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation |
| - | Review, | Var, | NA |
| 2536- | SDT, | Sonodynamic Therapy: Rapid Progress and New Opportunities for Non-Invasive Tumor Cell Killing with Sound |
| - | Review, | Var, | NA |
| 2551- | SDT, | Sonoporation: Past, Present, and Future |
| - | Review, | Var, | NA |
| 2550- | SDT, | Intracellular Delivery and Calcium Transients Generated in Sonoporation Facilitated by Microbubbles |
| - | in-vitro, | Nor, | NA |
| 2537- | SDT, | Design and Challenges of Sonodynamic Therapy System for Cancer Theranostics: From Equipment to Sensitizers |
| - | Review, | Var, | NA |
| 2548- | SDT, | Sonoporation, a Novel Frontier for Cancer Treatment: A Review of the Literature |
| - | Review, | Var, | NA |
| 2141- | Se, | Selenium and cancer risk: Wide-angled Mendelian randomization analysis |
| - | Review, | NA, | NA |
| 2140- | Se, | Selenium Exposure and Cancer Risk: an Updated Meta-analysis and Meta-regression |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid